Caroline Robert

Caroline Robert is a globally recognized melanoma expert who co-led the KEYNOTE-054 phase III trial establishing adjuvant pembrolizumab as a standard of care for resected high-risk stage III melanoma. Her research demonstrated that adjuvant pembrolizumab significantly improves recurrence-free survival compared to placebo in patients with resected stage IIIA-IIIC melanoma. She has investigated predictive biomarkers for adjuvant pembrolizumab benefit and long-term outcomes data from KEYNOTE-054 showing durable protection from recurrence. Her contributions to melanoma immunotherapy span from early pembrolizumab development through contemporary adjuvant and neoadjuvant strategies.